-
-
The ECG in the Figure was obtained from a 61-year-old woman who was being treated with flecainide for arrhythmia. Her tracing was interpreted as showing sinus tachycardia with 1° AV block, with the conduction disturbance being seen best in lead V1. How would you interpret this ECG?
-
Since its first clinical description in 1829 by Sir Charles Bell in England, Bell's Palsy has been surrounded by therapeutic controversy and its etiology has been shrouded in mystery. Recent literature, however, features evidence-based trials that enable emergency department clinicians to recommend more advanced treatment than ever before.
-
When the pediatric lumbar puncture (LP) is traumatic, confusion arises as to whether cerebrospinal fluid (CSF) white blood cells are from infection or from contaminating blood. To better identify patients with and without CSF pathogens, Mazor and colleagues studied 57 children ages 1 month to 13 years who had traumatic LPs (> 500 red blood cells [RBCs]/mm3) during evaluation for suspected meningitis.
-
Biosite (San Diego, California) and Beckman Coulter (Fullerton, California) signed an agreement for Beckman Coulter to manufacture and Biosite to commercialize a b-type natriuretic peptide (BNP) test for use on Beckman Coulters immunoassay systems.
-
According to the Carvedilol or Metoprolol European Trial (COMET), chronic heart failure (CHF) patients treated with the beta blocking agent carvedilol had a significant survival benefit 17% better than those taking the selective beta blocker metoprolol.
-
Advances in Cardiovascular Technology: Emerging Markets for the 21st Century, a sourcebook produced by the BBI group of Thomson BioWorld, publishers of Cardiovascular Device Update, received second-place honors in the Best Looseleaf Publication category of awards issued for 2002 by the Newsletter and Electronic Publishers Association, the major organization representing the worldwide newsletter industry.
-
BOSTON, Massachusetts The 83rd annual meeting of the American Association for Thoracic Surgery (AATS; Beverly, Massachusetts) provided one of the first forums for cardiac surgeons to discuss the future impact of the new drug-eluting coronary stents on patient management.
-
-
A second company earned U.S. regulatory approval in the embolic protection field last month, with Boston Scientifics (Natick, Massachusetts) FilterWire EX Embolic Protection System joining Medtronics (Minneapolis, Minnesota) PercuSurge GuardWire Plus system, which was approved by the FDA in June 2001.
